Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewise Therapeutics, Inc. (NASDAQ: EWTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Edgewise is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and serious cardiac conditions, and its filings offer detailed information on clinical progress, financial results, and corporate governance.
Investors can review current reports on Form 8-K that Edgewise files to announce material events, such as clinical data updates for sevasemten in Becker and Duchenne muscular dystrophies, progress in the EDG-7500 CIRRUS-HCM Phase 2 trial in hypertrophic cardiomyopathy, and initiation of Phase 1 studies for EDG-15400 in heart failure. Other 8-K filings describe financial results for specific quarters, appointments of new directors and executive officers, and equity-based compensation arrangements, including inducement grants under Nasdaq Listing Rule 5635(c)(4).
Through this page, users can also locate references to annual and quarterly reports (Forms 10-K and 10-Q) and related exhibits, where Edgewise discusses risk factors, liquidity, research and development expenses, and dependence on key product candidates such as sevasemten and EDG-7500. Disclosures frequently highlight that the company is clinical-stage, has not generated product revenue, and faces the typical uncertainties of drug development and regulatory approval.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand clinical, financial, and governance information. Users can also track insider and equity-related disclosures reported in 8-K exhibits and other filings to see how leadership and directors are compensated and how the company structures its incentive plans.
Edgewise Therapeutics focuses on small-molecule drugs for serious muscle diseases, highlighting three main programs and a broad patent estate. The company targets rare neuromuscular disorders like Duchenne and Becker muscular dystrophy and cardiac diseases driven by sarcomere dysfunction.
Lead candidate sevasemten, an oral fast skeletal myosin inhibitor, is in multiple late-stage studies for Becker and Duchenne, with Phase 2 data showing significant reductions in muscle-damage biomarkers and stabilization of functional scores, and a pivotal Becker cohort (GRAND CANYON) fully enrolled. EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, has Phase 2 data indicating large LVOT gradient and NT-proBNP reductions in both obstructive and non-obstructive HCM without meaningful declines in ejection fraction.
EDG-15400 is in Phase 1 for heart failure with preserved ejection fraction. Edgewise reports extensive global patent coverage on these assets, with key composition-of-matter patents extending into the 2040s. As of June 2025, non‑affiliate equity was valued at about $1.2 billion, and as of February 19, 2026, 107,270,521 common shares were outstanding.
Edgewise Therapeutics reported fourth-quarter and full-year 2025 results alongside major pipeline milestones in muscular dystrophy and cardiovascular programs. Cash, cash equivalents and marketable securities were $530.1 million as of December 31, 2025.
For Q4 2025, research and development expenses were $43.6 million, up from $37.5 million in the prior quarter, driven mainly by higher personnel costs and increased EDG-15400 and EDG-7500 clinical activity. General and administrative expenses rose to $12.4 million from $9.4 million.
The company reported a fourth-quarter net loss of $50.2 million, or $0.47 per share, compared with a net loss of $40.7 million, or $0.39 per share, in the preceding quarter. Edgewise highlighted upcoming catalysts, including GRAND CANYON pivotal data for sevasemten in Becker muscular dystrophy in Q4 2026, CIRRUS-HCM 12-week EDG-7500 data and Phase 1 EDG-15400 data in the first half of 2026.
Edgewise Therapeutics, Inc. reported a significant institutional holder in a Schedule 13G/A. Paradigm BioCapital Advisors LP and related entities disclosed beneficial ownership of 6,541,210 shares of Edgewise common stock, representing 6.2% of the outstanding shares as of December 31, 2025.
The filing states that Paradigm BioCapital International Fund Ltd. directly holds 5,778,924 shares, or 5.5% of the company. The ownership percentages are based on 105,868,434 shares of common stock outstanding as of October 31, 2025. The reporting group certifies that the shares are held on a passive basis, not to change or influence control of Edgewise.
Edgewise Therapeutics, Inc. director Edris Badreddin reported option exercises and related share sales. On January 21, 2026, he exercised multiple stock options for Edgewise common stock at exercise prices ranging from $0.39 to $1.93 per share, converting them into common shares held directly.
The same day, he sold shares of Edgewise common stock in several transactions marked with code "S". These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 24, 2025, at an average sale price of $29.44 per share, with individual trades occurring between $29.00 and $29.77. Following the reported transactions, Badreddin directly owned 19,820 shares of Edgewise common stock.
Eliem Therapeutics (symbol EWTX) has a holder planning to sell common shares under Rule 144. The notice covers 115,471 shares of common stock to be sold through J.P. Morgan Securities LLC on the Nasdaq market, with an approximate sale date of 01/21/2026. The aggregate market value of the planned sale is listed as 3,353,279, compared with 105,868,434 common shares outstanding.
The shares to be sold were acquired on 01/21/2026 through a stock option exercise from the issuer, paid for in cash on the same date. The person signing the notice represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or future operations.
Robert Michael Carruthers filed a Rule 144 notice to sell 183,867 shares of common stock of EWTX through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of
EWTX shareholder Robert Michael Carruthers has filed to sell 180,872 common shares through Morgan Stanley Smith Barney LLC on or about 01/15/2026 under Rule 144. The filing lists an aggregate market value of $4,804,322.06 for these shares, with 105,868,434 common shares of the issuer reported as outstanding.
The shares to be sold were acquired on 01/15/2026 by exercising options under a registered plan in two transactions of 166,665 and 14,207 shares, both paid in cash. Over the prior three months, Carruthers sold additional common shares in two transactions: 116,665 shares on 12/29/2025 for gross proceeds of $3,039,811.57 and 70,000 shares on 11/17/2025 for $1,566,586.00.
Edgewise Therapeutics, Inc. (EWTX) reported a routine equity compensation grant to a director on a Form 4. On November 19, 2025, the reporting person received stock options to purchase 45,150 shares of common stock at an exercise price of $22.34 per share. These options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, so full vesting occurs over three years as long as the director continues as a service provider through each vesting date. The options have an expiration date of November 19, 2035, meaning they can be exercised anytime after vesting and before that date, subject to the applicable plan and agreement terms.
Edgewise Therapeutics, Inc. (EWTX) director files Form 3 reporting no holdings. The filing states that director Christopher Nathan Martin, through his attorney-in-fact, filed an initial statement of beneficial ownership and reported that he does not beneficially own any Edgewise Therapeutics securities as of the event date.
Edgewise Therapeutics, Inc. (EWTX) reported that its Board of Directors appointed Christopher Martin as a Class I director, with his term running through the company’s 2028 annual meeting of stockholders. Martin, age 49, brings extensive commercial experience from roles at Verona Pharma, SK Life Science, Cempra, and Salix Pharmaceuticals, including leading launch strategies for several first‑in‑class products.
Martin was deemed independent under SEC and Nasdaq rules and has no related‑party transactions requiring disclosure. He will receive an annual cash retainer of